Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioblastoma 7Urinary Bladder Neoplasms 5Glioma 5Prostatic Neoplasms 4Lung Neoplasms 4Esophageal Neoplasms 4Burkitt Lymphoma 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Astrocytoma 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mouth Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Ganglioneuroblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Embryonal × Radiation × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡